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The Pathogenesis of Congenital 




Congenital anomalies present with significant financial, social, and moral issues 
and questions to the family and society and are difficult to rehabilitate. In utero 
exposure to teratogenic agents and infection are the two most important causes 
of nongenetic acquired anomalies presenting at birth. Teratogens such as drugs, 
adverse maternal conditions, and toxins are environmental factors that cause 
permanent structural or functional malformations or death of the embryo or fetus. 
Teratogens may cause significant congenital anomalies if encountered during the 
organogenesis period of 3–8 weeks of fetal life, which is the stage of tissues and 
organs formation, whereas minor morphological and functional disorders may 
occur with exposure during the fetal period of first 2 weeks. TORCH group infec-
tions (toxoplasmosis, others, rubella, cytomegalovirus, and herpes) are the most 
serious infectious diseases during pregnancy due to the severity of possible embryo-
fetal lesions. With expanding scientific knowledge and clinical experience about 
the association of these toxins and infections with significant, at times crippling 
congenital anomalies, the avoidance of exposure to pregnant mothers has become 
the most important part of their prevention and management.
Keywords: teratogens, drugs, toxins, alcohol, smoking, congenital infections, 
cytomegalovirus
1. Introduction
In utero exposure to teratogenic agents and infection are the two most important 
causes of nongenetic, acquired anomalies presenting at birth. The fetal response 
and susceptibility to such agents are variable, and the effects depend on the type, 
timing, and duration of intrauterine exposure [1, 2] (Figure 1). The end results of 
such exposures may be organ system malformations; aberrations in organ growth, 
function, and development; and even death. The developmental stage of organo-
genesis, which is characterized by rapid cellular differentiation and migration, is 
the most vulnerable period, as the actively dividing cells are highly sensitive to the 
adverse effects of noxious agents [3]. The effects of teratogens during the preim-
plantation embryonic phase of the first two postconceptional weeks might present 
as all or none, as the uterine implantation of a defective embryo may fail and the 
pregnancy end with undetected abortion, thus nullifying the possibility of congeni-
tal malformations [4, 5] (Figure 1).
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Congenital anomalies are health problems that are difficult to rehabilitate. They 
generate high treatment costs and might bring on huge financial and moral burdens 
to the family and society. According to the congenital anomalies survey conducted 
by the World Health Organization (WHO) in 193 countries in 2010, 270,000 of the 
3.1 million newborn deaths were caused by congenital anomalies [6]. In the United 
States, 2–3% cases of the 3–5% of children born with birth defects are attributed to 
environmental or iatrogenic teratogen exposure during the intrauterine (IU) life 
[7]. Most of the teratogen-induced anomalies are preventable.
2. Teratogenic agents
Teratogens may cause significant congenital anomalies if encountered during 
the organogenesis period of 3–8 weeks of fetal life, which is the stage of tissue 
and organ formations (Figure 1). Minor morphological and functional disorders 
may occur with exposure during the fetal period of the first 2 weeks [8]. Multiple 
factors come into play for the teratogens to impart their effects. These are the 
genetic specifications of the conceptus, the dose and duration of exposure, and 
the mechanism of action of the offending agent. Teratogens effectuate primarily 
by disrupting cell-specific biochemical metabolism and by compromising blood 
circulation which lead to cell death. They can destroy and deplete essential nutri-
ents, block enzyme activities, disrupt mitosis, interfere with nucleic acid functions, 
and derange membrane functions, osmolar balance, and energy production [9, 10]. 
Genetic differences in response to teratogens have been documented and may be 
due to the presence of genetic polymorphisms in the activities of enzymes involved 
in the excretion of toxic substances [11]. Animal studies have shown differences in 
the susceptibility to teratogen-induced damage within the same as well as between 
different species. Fetal hydantoin syndrome is detected in 5% of embryos exposed 
to phenytoin (PTN), and about 30% of them show some congenital anomalies, 
while more than half display no teratogenic effects [12]. Aspirin, corticosteroids, 
Figure 1. 
Sensitivity to teratogens during pregnancy.
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and some vitamins are teratogenic in mice and rats, but not in humans. Cleft palate 
and cleft lip are more common in mice with consanguineous matings [13].
2.1 Drugs
Drugs can directly affect the product of conception and cause malformation 
and/or embryo-fetal demise. They can impair the fetal development by compromis-
ing the transplacental transfer of nutrients and oxygen from the mother. They may 
diminish fetal blood supply and initiate premature myometrial contractions result-
ing in premature birth [14]. Drugs can play roles in the intrauterine development 
of gene-encoding proteins, thereby altering transcription regulation signals which 
adversely affect embryogenesis [15]. Drugs can exert their effects at different stages 
of cell development, namely, replication, proliferation, gene expression, signal 
transduction, programmed cell death, and cell migration (Table 1) [16, 17].
2.1.1 Phenytoin
Although the exact pathogenesis of phenytoin (PTN) embryo toxicity is unclear, 
some possible mechanisms have been proposed [18]. Phenytoin acts as a membrane 
stabilizer by inhibiting sodium (Na) and calcium (Ca) channels, as a result of which 
free radicals are released and cause endothelial damage, myocardial depression, 
bradycardia, and consequently fetal hypoxia. Phenytoin induces cytochrome P450 
activation which results in the release of teratogenic free radicals, sourced via the 
metabolism of epoxides, folate, and vitamin K in the liver [19, 20]. Phenytoin, like 
other antiepileptic agents, namely, valproic acid (VPA) and vigabatrin, induces 
Drug Most susceptible period Effects
Phenytoin Organogenesis 
(18–60 days)





Warfarin Second part of the first 
trimester (6–9 weeks)
Nasal hypoplasia, limb hypoplasia, optic 
atrophy, bone abnormalities, neurological 
impairment
Amphetamines All trimester Cleft palate, heart defects, intestinal atresias, 
and structural brain abnormalities
Sodium valproate Organogenesis 
(18–60 days)
Neural tube defect, cleft palate, atrial 




Skeletal and ocular defects, cleft palate
Aminopterin Organogenesis 
(18–60 days)
CNS, limb, and skeletal defects
ACE inhibitors Second. or third trimester 
(13th week term)




Cleft lift and palate abnormalities
Lithium First trimester Ebstein’s anomaly
Table 1. 
Some teratogenic drugs and their effects.
Congenital Anomalies in Neonates - Clinical Perspectives
4
carnitine deficiency in the fetus which may lead to cardiomyopathies and ventricu-
lar septum defects [21]. Infants born to women with mutations in the methylenetet-
rahydrofolate reductase (MTHFR) gene are at an increased risk for fetal hydantoin 
syndrome as its protein products compromise the metabolism of phenytoin and/
or its metabolites. Free radicals released as intermediate metabolites of phenytoin 
bind to deoxyribonucleic acid (DNA), proteins, and lipids and adversely affect the 
neurodevelopment. The wide variation in the presentation of anomalies related to 
PTN may be due to the genetic differences in the formation of free radicals, drug 
clearance, and repair mechanism. Fetal hydantoin syndrome can be seen in approxi-
mately 5–10% of infants with in utero exposure to phenytoin, whereas incomplete 
clinical syndrome can be seen in about one third of them [22]. The characteristic 
features of fetal hydantoin syndrome include microcephaly, craniofacial anomalies, 
hypertelorism, flattened nasal root, ptosis, wide mouth, cleft palate-lip, cardiac 
defects, urogenital malformations, and hypoplastic distal phalanx and nails. There 
is also an increased risk of neural tube defects (NTD) as this antiepileptic reduces 
fetal serum folate levels [23].
2.1.2 Valproic acid
Depending upon the dose and duration, the in utero exposure to VPA may 
increase the incidence of congenital malformations in neonates by 2–16 times 
[24]. The teratogenic effects of VPA on the fetus are typically caused by maternal 
ingestion of drug in doses over 1000 mg/day. However, adverse effects can be seen 
at lower doses of 500 mg/day as well. In one study, the rate of major congenital 
malformations with fetal exposure to VPA via maternal medication in the doses 
of <700 mg/day for 1 year was 6%, which increased to 10% when the doses were 
between 700 and 1500 mg and to 24% when over 1500 mg [25].
Like PTN the exact mechanism of action of VPA is unknown and various 
theories have been forwarded. Crudup et al. showed that VPA can increase 
γ-aminobutyric acid (GABA) levels in the brain via the inhibition of its catabolism 
[26]. VPA can directly inhibit voltage-gated sodium channels or bind to the proteins 
by acting as a histone deacetylase inhibitor (HDACi). HDACi can disrupt cell cycle, 
stop growth, and induce apoptosis [27, 28]. Furthermore, VPA induces chromatin 
changes and reduces the transcription of mRNA by converting chromatin segments 
to heterochromatin. The high affinity of valproic acid to folate receptors causes 
their competitive inhibition and increases the frequency of neural tube defects by as 
much as 20 times [29].
Valproic acid may cause multi-organ system anomalies, including those of cra-
niofacies (epicanthal fold, small wide nose, anteverted nostril, long philtrum, thin 
upper-thick lower lip, retroverted ears), extremities (polydactyly, arachnodactyly, 
rudimentary fingers), and spinal column (neural tube defects, spina bifida). Other 
important defects include those of cardiovascular (ventricular septal defect (VSD), 
patent ductus arteriosus (PDA), aortic coarctation), respiratory (tracheomalacia), 
and urogenital systems (inguinal hernia, hypospadias, cryptorchidism, incomplete 
fusion of the Müllerian duct). The incidence of meningomyelocele, especially lum-
bar or lumbosacral, is reported to be 1–2% with in utero fetal exposure during the 
first trimester [30, 31]. Developmental anomalies and autism are other teratogenic 
effects of VPA described in the literature.
2.1.3 Thalidomide
Thalidomide (TD), which is currently being used for the treatment of multiple 
myeloma and leprosy, was initially prescribed for pregnancy-associated nausea and 
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emesis in Europe, Asia, and America, without any preceding drug phase studies in 
the 1950s. Its teratogenic effects were first noticed in Europe in the early 1960s [32] 
when several case reports of phocomelia in babies born to mothers treated with 
TD during pregnancy were published. This revelation became a turning point in 
the history of pharmacovigilance. In November 1961, Lenz presented the specific 
features including limb anomalies in 52 in utero exposed infants to TD at a Pediatric 
Congress. This was followed by a publication documenting an association between 
the drug and congenital malformations in 1962 [33] (Figure 2). Subsequently, 115 
case reports of similarly affected infants in Germany, Belgium, Sweden, and the UK 
were published, and the drug was withdrawn from the market [34]. Thalidomide 
affected about 10,000–15,000 infants and caused death in more than half of them 
during this period.
The incidence of congenital malformations is 50% if 50 mg of TD is ingested 
during the postfertilization days of 20–36 [35]. If given earlier it may cause miscar-
riages as demonstrated in rats. More than 30 scientific theories for thalidomide 
embryopathy have been forwarded over the past 50 years [36]. DNA mutagenesis, 
chondrogenesis, nerve/neural crest toxicity, and inhibition of cell adhesion mole-
cules have been proposed as the potential mechanisms of thalidomide embryopathy. 
However, the most widely accepted theory is that of the antiangiogenic action of 
the drug on fetus [37]. D’Amato et al. showed that thalidomide inhibits angiogenic 
vascularization of the rodent cornea induced by a fibroblast growth factor protein. 
It is believed that thalidomide exerts its teratogenic effects by adversely affecting 
the embryonic blood vessels, which results in the disruption of vascularization 
during organogenesis leading to abnormal fetal growth and congenital malforma-
tions [38, 39]. The congenital anomalies caused by thalidomide are phocomelia, 
dementia, dysosmia, bone hypoplasia, cardiac malformations, ear malformations, 
splenic agenesis, gallbladder agenesis, and esophageal, duodenal, and anal atresia as 
well as stenosis [40].
2.2 Toxins
There has been a rapid progress in the awareness of adverse effects of a wide vari-
ety of environmental, medical, infectious, and nutritional toxins on the developing 
fetus since the end of the twentieth century. With the expanding scientific knowl-
edge and clinical experience about the association of these toxins with significant, 
at times crippling, congenital anomalies, the avoidance of exposure to pregnant 
mothers has become the most important part of their prevention and management. 
The congenital malformations associated with exposure to the current known toxins 
Figure 2. 
Phocomelia and amelia.
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are deafness, visual impairment, skeletal anomalies, and central nervous system 
(CNS) malformations, apart from embryonic loss and fetal demise [41].
2.2.1 Radiation
Radiation is a highly teratogenic toxic agent which exerts its adverse effects at 
cellular, subcellular, and molecular levels. It disrupts the molecular structure by 
both direct and indirect actions. No cell is known to be completely resistant to the 
toxicity of radiation. The risks are highest during the organogenesis phase [42], 
and the most vulnerable part of the cells to radiation injury is the highly active 
nucleus. The radiation-induced damage to the DNA may result in cell death, genetic 
mutations, and malformations, the severity and extent depending on the radia-
tion dose and the stage of cell development at the time of exposure. Chromosomal 
anomalies are observed in cells when they are exposed to radiation during mitosis 
and DNA molecule formation [43, 44]. Cellular interruption and suppression of cell 
growth are the most common manifestations of radiation exposure during mitosis. 
Bergonie and Tribondeau (1906) documented that the most sensitive cells to radia-
tion are the ones that are un- or underdifferentiated with undetermined function 
and morphology and are undergoing the highest mitotic activity [45]. The effects of 
radiation exposure during the first 14 days after fertilization are abnormal or failed 
embryo implantation resulting in miscarriage.
The dose is an important determinant of the radiation toxicity, and, accordingly, 
all pregnancies may not suffer from adverse effects [46]. As per the International 
Commission on Radiation Protection (ICRP), the chances of adverse or lethal 
effects in the preimplantation period of embryonic development are very low if 
the dose is less than 100 milliSieverts (mSv), and the actual threshold dose for the 
production of malformations is around 100 mSv [47]. The embryo is most suscep-
tible to radiation-induced congenital malformations during the postconceptional 
ninth day and sixth weeks, the phase of organogenesis. Cerebral structural and 
functional anomalies such as microcephaly and mental retardation occur following 
exposure to doses over 100 mSv during the 8–16 weeks of intrauterine life, whereas 
ocular and skeletal abnormalities result with doses exceeding 200 mSv. After the 
sixth week of pregnancy and when the major part of organogenesis is competed, 
radiation causes neurodevelopmental delays. It is stated that the therapeutic risks of 
radiation are minimal in doses less than 50 mSv (Table 2) [48]. These dose-effect 
relationships were demonstrated in animal experiments. In humans, microcephaly 
and mental retardation were the most common anomalies identified in children 
exposed to radiation during early conception in Hiroshima and Nagasaki survivors 
Gestational period (weeks) Effects Estimated dose amount
Preimplantation (0–2) Miscarriage or is not affected 50–100 mSv
Organogenesis (2–8) Congenital anomaly (skeletal system, 
genital, or eye)
200 mSv
8–15 Severe mental retardation (high risk) 60–130 mSv
8–15 Intellectual influence Reduction of 25 intelligence 
coefficients per Sv
8–15 Microcephaly 200 mSv
16–25 Severe mental retardation (mild) 250–280 mSv
Table 2. 
Effects of radiation doses according to the gestational age.
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after World War II. Other anomalies noted were low birth weight, cataract, genital 
and skeletal malformations, and microphthalmos [49]. Streffer et al. suggested that 
after organogenesis, the effects of exposure may be similar to the postnatal effects 
with no major congenital anomalies encountered. They reiterated that the mam-
malian embryo and fetus are highly radiosensitive and the nature and sensitivity 
of induced biological effects depend upon the dose and developmental stage at 
irradiation [50].
2.2.2 Alcohol
Alcohol is an important teratogen with multisystemic adverse effects. No 
amount of consumption is safe during pregnancy. In the USA, one “standard” 
drink contains approximately 14 g of pure alcohol. This translates to 12 ounces of 
regular beer (5% alcohol), 5 ounces of wine (12% alcohol), and about 1.5 ounces of 
distilled spirits (40% alcohol). The 2016 National Institute on Alcohol Abuse and 
Alcoholism has defined prenatal alcohol exposure as follows: ≥6 drinks per week 
for ≥2 weeks or ≥3 drinks per occasion on ≥2 occasions, started at 3 months before 
pregnancy, or at diagnosis, and continued until delivery [51]. The fetus eliminates 
alcohol poorly at a rate of only 3–4% of the maternal rate. Moreover, part of the 
alcohol excreted via the fetal urine into the amniotic fluid is swallowed back, thus 
recirculating it into the system, and a small volume of amniotic fluid alcohol is 
absorbed into fetal compartments via a transmembranous route. These factors 
make fetus specifically more vulnerable to the adverse effects of maternal alcohol 
consumption [52].
As with other teratogenic agents, the effects of alcohol in the fetus vary accord-
ing to the gestational age and the duration and dose of exposure [53]. Alcohol 
damages the structure, neuronal migration, and synaptogenesis in the develop-
ing CNS of the fetus. The consumption of two glasses of alcohol per day during 
pregnancy, especially the first 3 months, leads to the typical fetal alcohol spectrum 
disorder (FASD), which is characterized by structural, behavioral, emotional, and 
neurological problems in the offsprings [54]. The typical features of this syndrome 
are the minor facial anomalies, including short palpebral fissure, thinner upper lip, 
and flat philtrum. Significant pre- and postnatal growth retardation is a common 
feature, along with variable mental retardation which may manifest as a decrease 
in intelligence quotient, difficulties in perception, and delays in certain skills-
seeking tasks (Figure 3 and Table 3) [55, 56]. FASD may present with congenital 
cardiac defects as well, the most common being ventricular septal defect, atrial 
septal defect, conotruncal anomaly, and tetralogy of Fallot. The risk of conotruncal 
anomaly increases as per the amount of alcohol consumed during the periconcep-
tional period [57].
2.2.3 Smoking and secondhand smoking
Cigarette smoking during pregnancy remains a major worldwide problem 
despite a significant decrease in incidence as a result of an increasing awareness 
of its adverse fetal effects. It is estimated that around 10–24% of women smoke 
while pregnant [58]. Fetal exposure to nicotine negatively affects its growth and 
increases the risk of neonatal and infant mortality and morbidity [59]. Nicotine 
and carbon monoxide (CO) decrease the placental blood flow via the vasoconstric-
tive effects of catecholamines, which are released from adrenals by nicotine activa-
tion. Nicotine promptly crosses the placental barrier and reaches its maximum 
activity in the fetus within 30 min of exposure. The concentration of nicotine in 
the amniotic fluid is demonstrated to be six times higher at 88% compared to 15% 
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in the mother’s blood. Nicotine acts on the brain by binding to nicotinic acetylcho-
line receptors (nAChRs) in autonomic ganglia and at neuromuscular junction. The 
binding results in the release of neurotransmitters and important neuromodula-
tors, such as dopamine, adrenaline, acetylcholine, Seratonin (5- hydroxytryptamine), 
GABA, glutamate, and substance P [60].
Both nicotine and carbon monoxide induce degenerative changes and premature 
aging in the placenta. The degenerative changes are marked by an increased amount 
of collagen in the chorionic villi and the thickening of subtrophoblastic basement 
membrane [61]. Premature aging is suggested by the increase in the syncope buds 
and apoptosis in the placentas. Both premature aging and degenerative changes sig-
nificantly reduce the placental functional capacity and lead to multiple adverse fetal 
effects. The incidence of premature births is significantly higher in mothers who 
1. Fetal alcohol syndrome (FAS) (all conditions will be met)
A. Confirmation of alcohol use during pregnancy
B. The presence of characteristic minor facial anomalies (at least two of the following):
i. Short palpebral fissure (≤10th percentile)
ii. Thin upper lip (score 4 or 5 in the lip/philtrum guide)
iii. Straight philtrum (score 4 or 5 in the lip/philtrum guide)
C. Prenatal and/or postnatal growth retardation:
i. Length or weight ≤ 10th percentile
D. Mental development disorder or abnormal morphogenesis (at least one of the following):
i. Structural abnormalities in the brain
ii. Head circumference ≤ 10th percentile
2. FAS in which alcohol use cannot be confirmed during pregnancy
3. Partial FAS in which alcohol use is confirmed during pregnancy
4. Partial FAS in which alcohol use cannot be confirmed during pregnancy
5. Alcohol-related congenital disorders
6. Alcohol-related neurodevelopmental disorders
Table 3. 
Fetal alcohol spectrum disorders.
Figure 3. 
Fetal alcohol syndrome (© 2009 University of Washington. With permission, Susan Astley, PhD).
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smoke [62]. The results of a recent meta-analysis by Hackshaw et al. demonstrated 
that maternal smoking increases the risks for a variety of system malformations, 
including those of cardiovascular (cardiac septal defects, malformations of pulmo-
nary and tricuspid valves, and malformations of the great arteries), musculoskel-
etal (limb reduction, clubfoot), craniofacial (craniosynostosis, cleft lip and palate), 
and gastrointestinal (gastroschisis) [63].
2.3  Adverse maternal conditions: nutritional deficiencies, diseases, and 
infections
Nutrients taken during pregnancy can have significant and lasting effects 
on maternal and newborn health. Inadequate or excessive intake of nutrients if 
associated with consequent pathophysiological changes during pregnancy can 
bring about epigenetic changes in the fetus with adverse short- and long-term 
implications. Optimum intakes of energy and nutrients during pregnancy as 
well as during breastfeeding are essential for the initiation and maintenance of 
a healthy life during childhood. It may also protect against several adulthood 
diseases [9, 64].
2.3.1 Zinc
Zinc is essential for normal fetal growth and development. It is a component of 
over 200 enzymes which take part in the formation and release of various pro-
teins, hormones, and neuropeptides. The element is involved in the transcription 
process in which a gene’s DNA sequence is copied to make an RNA molecule. Zinc 
is required for proper cell division, growth, and differentiation. Severe zinc defi-
ciency is embryotoxic and teratogenous and may cause lethal fetal developmental 
and structural anomalies [65].
It has been shown that maternal zinc deficiency can affect embryonic protein 
and DNA synthesis and cause chromosomal damage characterized by terminal 
deletion [66]. Maternal zinc deficiency is associated with increased apoptosis in 
the embryonic cells. TUNEL analysis has shown that cell death is increased in 
the peri-implantation embryos if the cultured cells have low zinc levels [67]. The 
cell cycle may not be adversely affected if the maternal zinc deficiency is short 
term [68]. In zinc deficiency, the formation of free radicals is increased as they 
cannot bind to the membranes and intracellular regions of redox-active metals, 
such as copper and iron [69], which results in increased oxidative stress and 
teratogenicity. Zinc can prevent oxidation of numerous proteins, including zinc 
finger transcription factors of redox-sensitive cysteine and sulfhydryl groups. 
Zinc is a component of copper-zinc superoxide dismutase and is the regulator 
of metallothionein, a metal-binding protein which has important roles in the 
execution of various physiological processes and in the prevention of stress [70]. 
Metallothionein releases zinc, which plays a central role in the antioxidant defense 
system during oxidative stress. Inadequate zinc uptake of the mother leads to 
a decrease in the circulating zinc levels which may adversely affect the neural 
tube development of the fetus as demonstrated in both animals and humans. In 
humans, the risk of neural tube defects is found to be increased in women with 
acrodermatitis enteropathica, a rare genetic disorder of zinc metabolism. It is 
noted that the prevalence of neural tube defects is higher in Africa and the Middle 
East, where zinc intake is chronically low due to ecological reasons [70, 71]. The 
relationship between zinc deficiency and cleft palate and lip was demonstrated in 
a study which showed the zinc levels in the blood of such infants and their moth-
ers to be significantly low [72].
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2.3.2 Folic acid (FA)
Folic acid, a group B vitamin, plays an important role in the production of new 
cells by assisting in the production of DNA and RNA that control cell proliferation 
[73]. It also works with vitamin B12 to form hemoglobin in erythrocytes. It has a 
protective effect against heart diseases. It decreases the risk of birth of infants with 
neural tube defects (spina bifida), obstructive urinary tract anomalies, limb defi-
ciencies, orofacial clefts, and congenital hypertrophic pyloric stenosis [74]. After 
absorption, folic acid is carried as a monoglutamate in the blood and is converted to 
various compounds in the cell, the most important being the reductase enzyme, tet-
rahydrofolate (THF). THF functions as the donor of single carbon units at various 
steps of DNA synthesis, which is required for the synthesis of purines, thymidylate 
and hence thymine [75, 76].
Research on the effect of folic acid on NTD began in the 1980s when studies 
showed that FA is effective in preventing both primary NTD and its recurrence 
[77]. In a multicenter randomized controlled study which included 1200 women 
with a history of NTD in their prior pregnancies, FA intake in the dose of 0.4 mg/
day started at least 1 month before conception and continued during the first 
3 months of pregnancy reduced the risk of NTD by 3.6 times [78]. In a cohort study 
in China, which included approximately 250,000 women, it was demonstrated that 
maternal intake of 0.4 mg folic acid reduces the risk of NTD in the fetus by 85% in 
high-prevalence areas and by 40% in low-prevalence areas [79, 80]. Folic acid has 
been also reported to reduce the incidence of CHD if used during the preconcep-
tional period [81]. The use of folic acid antagonist drugs, which cause the inhibition 
of dihydrofolate reductase enzyme, increases the frequency of CHD.
2.3.3 Maternal diabetes mellitus
The discovery of insulin in 1922 and advances in obstetrics and neonatal 
intensive care reduced perinatal mortality in pregnancies complicated by diabetes 
mellitus by approximately 30 times. By maintaining maternal euglycemia, such 
pregnancies were able to continue until term with a resultant decrease in prematu-
rity-related complications including respiratory distress syndrome [82]. Still, peri-
natal mortality in diabetic women continues to be about twice that of nondiabetic 
women. Also spontaneous abortion rates are higher in diabetic women, especially if 
the glycemic control is suboptimal in the periconceptional period [83].
Hyperglycemia has been shown to induce oxidative stress in the developing 
embryonic and fetal cells and tissues in animal studies, with the release of reactive 
oxygen species (ROS). Increased concentrations of ROS induce organ malformation 
and birth defects via membrane changes, mitochondrial dysfunction, and the ini-
tiation of abnormally programmed cell death (apoptosis). In mice models injected 
streptozotocin (STZ) to induce type 1 diabetes hyperglycemia caused changes in 
the yolk sac, as well as abnormalities in the endoplasmic reticulum and premature 
aging. It induced oxidative phosphorylation in the mitochondria and increased the 
concentration of ROS [84]. If appropriate glycemic control is maintained dur-
ing the third and sixth weeks of pregnancy, the periods when the embryo is most 
susceptible to teratogens, congenital anomaly rates are found to be the same as in 
the general population [85]. Vitamins E and C, which are antioxidants, have been 
shown to reduce hyperglycemia-related anomalies in animal models. Some prosta-
glandins may have the same effects.
The incidence of congenital anomalies, which is 1–2% in the general population, 
is 4–8 times higher in infants of mothers with pregestational diabetes. Congenital 
anomalies are the most important cause of perinatal death in pregnancies 
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complicated with diabetes mellitus [86]. Although anomalies can be seen in all 
organ systems in the neonates of diabetic mothers, the most important ones are 
those in the cardiac and central nervous systems (Table 4). Caudal regression 
syndrome is a rare congenital anomaly caused by maternal diabetes. No increase in 
the rate of congenital anomalies is seen in normoglycemic mothers or those with 
gestational diabetes occurring after the first trimester, which reiterates that glyce-
mic control during embryogenesis plays a major role in the pathogenesis of fetal 
anomalies. Congenital anomalies are found to be more common in pregnant women 
with high HbA1c levels in the first trimester with a direct relationship with its level 
and the rate of anomalies [87].
2.3.4 Maternal phenylketonuria (PKU)
Maternal phenylketonuria is one of the most common teratogenic syndromes 
of pregnancy. Phenylalanine crosses the placenta by active transport and increases 
the level of phenylalanine in fetal blood by 70–80% of maternal phenylalanine 
concentration [88]. Increased levels of phenylalanine are toxic and teratogenic to 
the developing fetus. Spontaneous abortions are observed in 24% of pregnancies 
with phenylketonuria, and in those who survive, microcephaly is found in 73%, 
mental retardation in 92%, congenital heart diseases in 12%, and intrauterine 
growth retardation in 40% of the offsprings [89]. If maternal phenylalanine 
levels are well controlled before conception and during pregnancy, the incidences 
of microcephaly and abnormal physical and neurological fetal development are 
significantly reduced. The prognosis is best in infants of mothers with a blood 
phenylalanine level of 120–360 μmol/L prior to pregnancy with no increase in the 
risks, while the prognosis is poor in those infants whose mothers had a phenyl-
alanine level exceeding 360 μmol/L during pregnancy. Severe congenital heart 
diseases were reported in infants born to untreated pregnant women with high 
blood phenylalanine levels, especially if the diet restriction was not started until 
the 7th and 18th weeks of gestation. There is no increase in the risk in pregnant 
women with phenylalanine level 120–360 μmol/L during the first 8 weeks of 
pregnancy. Serious fluctuations in maternal phenylalanine levels in pregnancy also 
have a negative impact on prognosis [90].
In pregnant women with phenylketonuria, sapropterin dihydrochloride, an 
orally active synthetic form of (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin, has 
been used in the doses of up to 20 mg/kg/day, in combination with a restricted diet 
for therapy, and the short-term results have been good. Large neutral amino acid 
• Cardiac anomalies
• Central nervous system anomalies
• Renal anomalies
• Gastrointestinal abnormalities




• Atrial septal defect
• Ventricular septal defect









Congenital anomalies seen in children of diabetic mothers.
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(LNAA) treatment, which is one of the other dietary alternatives used in patients 
with phenylketonuria, is contraindicated in pregnancy because it does not reduce 
blood phenylalanine levels to safe levels [91].
3. Maternal infections
Congenital anomalies caused by intrauterine exposure to infectious pathogens, 
especially certain viruses, continue to be a significant clinical problem around the 
world, despite the availability of vaccines (effective against rubella, varicella-zoster, 
and hepatitis B viruses), drugs (against herpes, toxoplasma, and HIV), and specific 
and sensitive immunological diagnostic tests for the majority of them. With the 
help of highly sensitive diagnostic procedures, the incidence of intrauterine infec-
tions during pregnancy is estimated to be about 12–20%. These infections cause a 
wide range of major anomalies and dysfunctions, including deafness, blindness, 
neurodevelopmental aberrations, growth failure, and congenital cardiac defects 
[92]. These diseases have been traditionally dealt with under the title of TORCH 
complex [93] representing toxoplasmosis; other (syphilis, parvovirus); R, rubella 
(German measles); C, cytomegalovirus; H, herpes simplex virus (Table 5).
The fetus and embryo are highly susceptible to infections, especially during the 
organogenesis period, while those encountered earlier may end in abortion. The 
fetus does not synthesize IgG and cannot adequately synthesize IgM and IgA until 
the second half of pregnancy. It has a very poor cellular immunity and the produc-
tion of the necessary cytokines is suboptimal [94]. Some pathogens may infect the 
mother and the placenta without showing any clinical symptoms in mother and lead 
to miscarriage, congenital anomalies, preterm birth, fetal hydrops, and premature 
rupture of the membrane.
3.1 Toxoplasmosis
Congenital toxoplasmosis occurs due to the transplacental passage of acute 
maternal infection with the protozoan organism Toxoplasma gondii to the fetus. 
In neonates, it presents with a wide spectrum of clinicopathological features. It 
may be clinically asymptomatic and present in a serologically detected form only, 
at times, to manifest clinically only in later years. On the other end, it may display 
severe multisystem involvement with debilitating features, such as chorioretinitis, 
hydrocephalus, and intracranial calcifications [95]. The severity of fetal infection 
depends on the gestational age during the parasitemia. In early pregnancy, the pla-
centa is an effective barrier to the parasite. The risk of congenital infection increases 
with increasing gestational age, the incidence being 15–17% in the first, 25% in the 
second, and 65% in the third trimester [96]. However, the severity and sequelae of 
the infection are much higher if encountered during early pregnancy. The incidence 
• Cytomegalovirus
• Human immunodeficiency virus (HIV)
• Herpes simplex virus (HSV)
• Toxoplasma gondii (Cong. toxoplasmosis)
• Zika virus
• Varicella-zoster virus (VZV)
• Trypanosoma cruzi (Cong. Chagas disease)
• Parvovirus
• Rubella
• Treponema pallidum (Cong. syphilis)
Table 5. 
Some strains of infection causing congonse to teratogens are very diverse and depend on the genetic sensitivity 
and severity of exposure.
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of organ anomalies is 75% with the fetal infection in the first trimester and 5% if the 
infection happens during the third trimester. Overall, organ anomalies in congenital 
toxoplasmosis can be detected in 10–20% of infected fetuses. Preterm birth and 
intrauterine growth retardation are other complications of intrauterine toxoplasmo-
sis [97]. Fetal infection during the first trimester of pregnancy may result in miscar-
riage or otherwise present as congenital infection with organ abnormalities specific 
to toxoplasmosis. Fetal infection occurring in the third trimester of pregnancy is 
often mild and asymptomatic depending upon the maturation of the fetal immune 
system and may at times only be serologically detected [98]. In addition, clinical 
symptoms may appear months or even years after birth. In a prospective study, it 
was reported that visual disturbances developed and detected during the regular 
well-child visit examinations of newborns asymptomatic at birth were diagnosed by 
serological to be due to toxoplasma by age as late as 20 years.
Other features of congenital toxoplasmosis are hydrocephalus, corpus callosum 
agenesis, cerebral calcification, microcephaly, intrauterine growth retardation, 
and nonimmune hydrops fetalis (Figure 4) [96, 99]. Pathologically, the placenta 
becomes first infected and appears to be pale, sludge-like, and edematous. Placental 
vasculitis along with granulomatous inflammatory lesions characterized by poly-
morphonuclear and lymphocyte infiltration in chorionic villi is specific for the dis-
ease. Following fetal transmission, fetal vasculitis develops [100], and the spreading 
trophozoites tend to settle in the brain and eyes. They form a granulomatous 
infectious lesion in the brain and its membranes. Eventually tissue necrosis happens 
around the parasite followed by fibrosis. These pathological processes cause con-
genital toxoplasmosis-specific microcephaly, cerebral calcifications, hydrocephalus, 
and chorioretinitis. It is reported that brain damage is more prominent in fetal 
infection before the 18th week of gestation. Eyes are the most commonly involved 
organ in congenital toxoplasmosis in which melanin pigment distribution disorder 
in the uvea and yellow-white edematous retinitis in the retina can be detected 
[101]. Microphthalmia and optic nerve atrophy may develop in infection encoun-
tered during early pregnancy. Deafness may develop in infants due to internal ear 
involvement. Skeletal muscles and myocardial infections are frequently involved. 
Moderate pneumonitis emulating viral pneumonia can be detected in the lungs. The 
liver usually enlarges and may present with pathological changes such as bile stasis, 
extramedullary hematopoiesis, dystrophic calcification, and portal fibrosis, while 
the pancreas, genital organs, urinary system, and gastrointestinal organs are gener-
ally not affected by the organism. The lymphoid tissue is affected and splenomegaly 
and adenopathy are commonly seen [102]. Clinically, fever, jaundice, espy direct, 
respiratory distress due to lung involvement, cardiovascular compromise due to 
myocarditis, hydrocephalus, and at times convulsions may be seen during neonatal 
period and in later life. In childhood, retardation is evident in mental and physical 
development. Vision and hearing disorders may occur in later life [103].
Figure 4. 
Hydrocephalus, chorioretinitis, and intracerebral calcification findings in congenital toxoplasmosis.
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3.2 Rubella
Despite the availability of an effective vaccine, over 100,000 cases of congenital 
rubella syndrome are reported every year. Congenital rubella infection occurs via 
transplacental transmission of the RNA virus to the fetus during maternal viremia 
[104]. The infection may be asymptomatic, present with mild common cold-like 
symptoms, or devastating. Clinical features such as fetal-neonatal cataract and 
glaucoma, microphthalmia; patent ductus arteriosus, cardiac septal defects, pul-
monary vascular stenosis, sensorineural deafness, fetal growth restriction, throm-
bocytopenia, anemia, hepatosplenomegaly, hepatitis, direct hyperbilirubinemia,  
chronic diffuse interstitial pneumonia, osseous changes, and even chromosomal 
abnormalities are grouped in congenital rubella syndrome. Fetal infection is found 
to cause necrosis, apoptosis, and division errors of cells involved in organogenesis, 
resulting in malformations. The mitotic activity is noted to be reduced in rubella-
infected cells. Another potential mechanism is that of a direct viral invasion into 
vasculatures causing tissue necrosis without inflammation (Figure 5) [105]. The 
capsid of the rubella virion (RV) plays an important role in mitochondrial damage 
and viral replication complexes, as evidenced by immunogold electron microscopy 
and indirect immunofluorescence studies. Cardiolipin is a phospholipid associated 
exclusively with mitochondria, and its presence in rubella virions suggests the 
involvement of the internal mitochondrial membrane of cells in viral proliferation. 
Both the mitochondrial distribution and morphology are abnormal in RV-infected 
cells, and the mitochondria tend to cluster in the perinuclear region along with 
viral replication complexes. In advanced infection electron-dense plaques between 
opposing mitochondria are formed, and the mitochondrial cristae may be lost in 
RV-infected cells [106]. The risk of congenital malformation is low after 17 weeks 
of IU life. It is thought that the immune response mechanisms (immunoglobulins 
like IgM, IgG, and IgA, T cells, natural killer cells, and interferons) appear during 
the second half of pregnancy and are not sufficiently mounted against the infection 
during the first trimester [107].
3.3 Parvovirus
Parvovirus, a non-enveloped single-stranded DNA virus, is the only member of 
the Parvoviridae family known to cause human disease. Failure to produce the virus 
in cell culture has made it difficult to elucidate the pathophysiology. The symptoms 
of parvovirus B19-related infection are usually related to the host’s immunological 
and hematological status. Since the immunological functions of the fetus are not 
optimum, parvovirus B19 infection may cause intrauterine infection, presenting as 
fetal anemia, hydrops fetalis, congenital malformations, and at times fetal-neonatal 
death [108].
Figure 5. 
Chorioretinitis, cataract, and blueberry muffin skin rash due to congenital rubella.
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The vertical transmission of acute infection during pregnancy happens in 
17–33% of the cases of maternal infection. Intrauterine infection is often asymp-
tomatic. The fetus is highly susceptible to erythroid hypoplasia due to parvovirus 
B19 infection, and due to the shorter life span of fetal erythrocytes and the destruc-
tive effect of the virus, especially on rapidly proliferating erythrocytes, severe 
aplastic anemia may develop with the consequent hydrops fetalis. In addition to 
anemia, thrombocytopenia, leukopenia, elevated transaminase, and increased 
bilirubin, espy direct may also occur. Intrauterine parvovirus infections may also 
cause central nervous system anomalies. Fetal loss rate due to parvovirus B19 infec-
tion in pregnancy has been reported to be 3–9% and that of hydrops fetalis as 18% 
[109]. Overall the short-term prognosis of neonates with intrauterine parvovirus 
B19 infections is reported to be good.
If parvovirus B19 is diagnosed during pregnancy, serial fetal monitoring by 
Doppler ultrasonography to measure the fetal middle cerebral artery flow velocity 
in order to evaluate the need of intrauterine fetal blood transfusion is important. 
The mortality is reduced from 50 to 18% with intrauterine erythrocyte transfusion 
in conditions of hydrops and/or anemia detected antenatally. One transfusion is 
often sufficient [110]. The infection usually does not cause intrauterine death if 
appropriate transfusion and other supportive treatments are provided, and the 
fetus if born alive has good prognosis [109, 111]. Currently, no specific antiviral 
agent or vaccine is available for parvovirus B19.
3.4 Cytomegalovirus (CMV)
CMV is the most common organism causing congenital infection around the 
world. The frequency is reported as 5–12/1000 live births. The risk of transmission 
increases with increasing gestational age, but the severity of fetal disease decreases. 
Approximately 10–15% of the fetuses infected in early pregnancy are symptomatic 
at birth, and in those cases severe systemic invasive disease marked by intrauterine 
growth restriction, hepatosplenomegaly, cholestasis, transaminitis, abnormal liver 
function tests, pneumonia, pancytopenia, hemolytic anemia, petechia, purpura, 
and central nervous system anomalies is noted [112]. Central nervous system 
findings in congenital CMV infection are quite diverse. Microcephaly, sensorineural 
hearing loss, chorioretinitis, and convulsion are the most common presentations. 
Abnormal neuroradiological findings, including ventriculomegaly-hydrocephalus, 
increased periventricular echogenicity and calcification, white matter involve-
ment, and lenticulostriate vasculopathy, are detected in 70% of the cases. Neuronal 
migration anomalies, temporal cystic periventricular leukomalacia, occipital 
intraventricular septa, cerebral atrophy, corpus callosum dysgenesis, and cerebellar 
hypoplasia are other relatively uncommon findings [113].
The inflammation process in the placenta infected with CMV is character-
ized by ICAM-1 expression on the membranes of placental trophoblasts, with 
enhancement in the adhesion of maternal blood cells [114]. During the mother’s 
primary infection, virus-bearing infectious leukocytes transmit CMV infection 
to the trophoblasts, and through the trophoblasts, the CMV reaches the stromal 
fibroblasts and fetal endothelial capillary cells [115]. Further in the process the virus 
is directed toward and proliferates in the major target fetal organs, namely, the 
brain, liver, inner ear, spinal cord, kidney, and the vascular epithelium. Viral DNA 
replication takes place in the infected organs with the production of infectious viral 
progeny. Neurons, oligodendroglia, microglia/macrophages, and neural progenitor/
stem cells, especially astrocytes, are particularly predisposed to CMV infections 
and may act as hosts in the replication and assist in the spread of the virus. The 
activated apoptosis during organogenesis is the important mechanism that leads 
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Figure 6. 
Congenital CMV-induced chorioretinitis, intracerebral calcifications, and blueberry muffin skin rash.
to malformations [114, 116]. The sensitivity of CMV IgM test, which is frequently 
used for the diagnosis of congenital CMV infection, is low, and the false positivity 
rate is high. Urine and saliva cultures for the virus are the recommended investiga-
tions for the identification of infection (Figure 6) [113, 116].
The Infectious Diseases Committee and the American Academy of Pediatrics 
recommend that ganciclovir treatment be considered in patients with con-
genital CMV infection with symptomatic central nervous system involvement 
(microcephaly, intracranial calcification, hearing impairment, and retinitis). 
Ganciclovir is a deoxyguanosine analogue and the first antiviral drug shown 
to be effective in the treatment of CMV infection in humans. It is first phos-
phorylated to ganciclovir monophosphate by a viral kinase encoded by the CMV 
gene UL97 during infection. Then cellular kinases catalyze the formation of 
ganciclovir diphosphate, and ganciclovir triphosphate is a competitive inhibi-
tor of deoxyguanosine triphosphate incorporation into DNA and preferentially 
inhibits viral DNA polymerases. Ganciclovir triphosphate inhibits the binding of 
deoxyguanosine triphosphate to viral DNA, slows viral DNA chain construction, 
and forms noninfectious viral DNA fragments. The concentration of ganciclovir 
triphosphate in infected cells is 10 times that of uninfected cells with a half-life 
in the cell longer than 24 hours [117]. Ganciclovir triphosphate also serves as a 
poor substrate for chain elongation, thereby disrupting viral DNA synthesis via 
a second route. However, clinically, ganciclovir treatment remains controversial 
in congenital CMV infection due to the need of long-term intravenous therapy, 
frequency of side effects, and limited healing from the infection. The use of 
valganciclovir, the L-valyl ester of ganciclovir, which is rapidly metabolized to 
ganciclovir in the body after oral administration, is increasing as with this treat-
ment the need of parenteral therapy, hospitalization, and the risk of catheter-
related infection are eliminated. The antiviral therapy may reduce the risk and 
duration of hospitalization in infants and is also reported to have a positive 
long-term effect on hearing [117, 118].
3.5 Varicella-zoster
The incidence of varicella infection in pregnancy is approximately 
0.4–2.4/1000. The infection can result in severe fetomaternal complications. 
Spontaneous abortion with varicella infection is observed in the first trimester 
[119]. Congenital varicella syndrome occurs secondary to infection in the first two 
trimesters, and the infection is thought to result from the reactivation of varicella 
and invasion of the placenta, similar to the mechanism of herpes zoster. The 
syndrome generally presents with an abnormal development of musculoskeletal 
system, dermatomal pattern of skin lesions, and segmental dysfunction of somatic 
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and autonomic nervous systems [120]. About 2% of fetuses exposed to the virus 
during the first 20 weeks of pregnancy (particularly during the 6th–20th week 
of gestation) may develop congenital varicella syndrome if the mother had no 
prior exposure to varicella. If varicella-zoster virus (VZV) infection occurs later 
during pregnancy (i.e., in the middle of the second or in the third trimester), the 
fetal immune system may be able to mount a response to the invading organism, 
typically resulting in a benign course. Embryopathy is not reported after 28 weeks. 
In one study, the incidence of varicella syndrome due to varicella infection during 
the first 20 weeks of pregnancy was reported as 0.91%, and the syndrome was not 
observed after 28 weeks [121]. In congenital varicella syndrome, the frequencies 
of occurrences of various systemic anomalies are as follows: skin lesions approxi-
mately 70%; limb hypoplasia 46–72%; nervous system abnormalities, such as 
cortical atrophy, microcephaly, and mental retardation, 48–62%; eye anomalies 
such as microphthalmia, cataract, and chorioretinitis 44–52%; and muscle hypo-
plasia, gastrointestinal, genitourinary, and cardiovascular system abnormalities, 
and developmental delay 7–24% [122].
3.6 Zika virus
In 2016, the US Centers for Disease Control and Prevention pronounced Zika 
virus infection as a risk for severe CNS defects in the fetuses of infected mothers. 
After crossing the placenta, the virus proliferates in the fetal brain tissues and 
infects the progenitor neural cells, leading to the growth failure and death of neural 
cells [123]. Although very few cases of Zika embryopathy are reported, the Zika 
virus-related CNS abnormalities are noted to be as follows: microcephaly, ven-
triculomegaly, cerebral calcifications, absent corpus callosum, and atrophy of the 
cerebellum and brainstem.
4. Summary
Congenital anomalies present with significant financial, social, and moral issues 
and questions to the family and society and are difficult to rehabilitate. In utero 
exposure to teratogenic agents and infection are the two most important causes of 
nongenetic, acquired anomalies presenting at birth. Teratogens are environmental 
and other agents that can cause structural or functional anomalies, or even demise 
in the embryo or fetus. TORCH (toxoplasmosis, others, rubella, cytomegalovirus, 
herpes) and other more recently identified infections during pregnancy may pres-
ent with embryo-fetal systemic lesions of varying severity and result in significant 
morbidity and mortality. Most of the teratogen-induced and several infection-
associated anomalies are preventable. Multiple factors determine the occurrence, 
presentation, and severity of congenital malformations in neonates who are 
exposed in utero to teratogens or infections. The individual response to teratogens 
is very diverse and depends on the genetic sensitivity of the product of conception 
and the severity of exposure.
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